Guardion Health Sciences, Inc. , is a clinical nutrition and diagnostics company. Guardion offers a portfolio of science-based, clinically supported nutrition, medical foods, and diagnostic products that support healthcare professionals, their patients, and consumers in achieving health goals. Guardion's commercial and developmental initiatives are supported by equally impressive scientific and medical advisory boards, led by seasoned business executives and physicians with many years of experience. This combination of expertise and scientific knowledge forms the foundation of Guardion's growing position within the eye care industry and the clinical nutrition marketplace.
Company profile
Ticker
GHSI
Exchange
Website
CEO
David W. Evans
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Guardion Health Sciences, LLC
SEC CIK
Corporate docs
Subsidiaries
VectorVision Ocular Health, Inc. • Transcranial Doppler Solutions, Inc. • NutriGuard Formulations, Inc. • Viactiv Nutrititionals, Inc. ...
IRS number
474428421
GHSI stock data
Latest filings (excl ownership)
8-K
Guardion Health Sciences Announces Appointment of Former Neutrogena and Coca-Cola Executive Jan Hall
30 May 23
8-K
Guardion Health Sciences Announces Financial Results
16 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Results of Operations and Financial Condition
20 Apr 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
3 Apr 23
8-K
Other Events
7 Mar 23
8-K
Other Events
24 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
6 Jan 23
Transcripts
Latest ownership filings
4
Janet Hall
31 May 23
3
Janet Hall
31 May 23
SC 13G
Hudson Bay Capital Management LP
8 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Bradley Louis Radoff
11 Jan 23
3
Bradley Louis Radoff
11 Jan 23
SC 13G/A
Radoff Bradley Louis
10 Jan 23
SC 13G
Radoff Bradley Louis
30 Nov 22
4
Michaela Griggs
21 Jun 22
4
Donald A Gagliano
21 Jun 22
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 8.77 mm | 8.77 mm | 8.77 mm | 8.77 mm | 8.77 mm | 8.77 mm |
| Cash burn (monthly) | 2.38 mm | (no burn) | 488.00 k | 1.36 mm | 626.40 k | 591.63 k |
| Cash used (since last report) | 5.18 mm | n/a | 1.06 mm | 2.96 mm | 1.37 mm | 1.29 mm |
| Cash remaining | 3.59 mm | n/a | 7.71 mm | 5.82 mm | 7.41 mm | 7.48 mm |
| Runway (months of cash) | 1.5 | n/a | 15.8 | 4.3 | 11.8 | 12.7 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 23 |
| Opened positions | 6 |
| Closed positions | 3 |
| Increased positions | 3 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 199.85 mm |
| Total shares | 15.99 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Hudson Bay Capital Management | 6.65 mm | $0.00 |
| Intracoastal Capital | 5.00 mm | $0.00 |
| Renaissance Technologies | 1.67 mm | $242.00 k |
| Radoff Bradley Louis | 620.00 k | $87.00 k |
| BLK Blackrock | 501.45 k | $72.76 mm |
| Vanguard | 288.28 k | $41.83 mm |
| BCS Barclays | 250.00 k | $36.00 k |
| Millennium Management | 196.48 k | $29.00 k |
| Geode Capital Management | 169.87 k | $25.00 k |
| UBS UBS Group AG - Registered Shares | 152.59 k | $22.89 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 30 May 23 | Janet Hall | Stock option Common Stock | Grant | Acquire A | No | No | 6.01 | 10,000 | 60.10 k | 10,000 |
| 10 Jan 23 | Radoff Bradley Louis | Common Stock | Buy | Acquire P | No | No | 7.9989 | 13,270 | 106.15 k | 217,900 |
| 10 Jan 23 | Radoff Bradley Louis | Common Stock | Buy | Acquire P | No | No | 7.3112 | 18,630 | 136.21 k | 204,630 |
| 9 Jan 23 | Radoff Bradley Louis | Common Stock | Buy | Acquire P | No | No | 7.1948 | 20,838 | 149.93 k | 186,000 |
| 9 Jan 23 | Radoff Bradley Louis | Common Stock | Buy | Acquire P | No | No | 6.7762 | 63,983 | 433.56 k | 165,162 |
| 16 Jun 22 | Michaela Griggs | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.147 | 16,667 | 2.45 k | 16,667 |
News
Guardion Health Sciences Q1 EPS $0.42 Up From $(3.50) YoY, Sales $3.19M Up From $2.38M YoY
15 May 23
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
28 Mar 23
Stocks That Hit 52-Week Lows On Monday
20 Mar 23
Stocks That Hit 52-Week Lows On Friday
10 Mar 23